Riding the New Wave of

Life Sciences Mergers and Acquisitions

Evaluating, Negotiating, and Consummating Successful Deals

Wednesday, March 14, 2007

About

Close the deal - Ensure successful and profitable life sciences mergers and acquisitions

In the past year, the life sciences industry has seen a marked increase in M&A activity. Life sciences companies have already spent billions of dollars on these deals. Due to the increased price and complexity of collaborations, many life sciences companies are now turning to M&As as either an exit strategy or a way to grow their business.

American Conference Institute's Riding the New Wave of Life Sciences Mergers and Acquisitions will keep you well prepared by bringing you thoughtful, targeted and in-depth analysis. You also will benefit from the detailed written materials prepared specifically for this event. Take this opportunity to get the most updated and comprehensive information and advice you need regarding life sciences mergers and acquisitions.

Negotiating M&As in the life sciences arena is significantly different from deals in other industries. For life sciences companies, you need to know how to handle the unique challenges in valuing and conducting an accurate due diligence on a pipeline. In addition, there are specific regulatory and antitrust concerns that arise in life sciences companies that must be considered with an M&A, as well as distinctive representations and warranties in your deal.

Understand the nuts and bolts of M&A deals

For any M&A deal, there are a number of factors that need to be addressed. Before beginning any M&A, the company needs to consider the business reasons for entering into the transaction as well as the best structure for the deal. Ensuring a workable post integration process is also essential to a successful deal.

Contents & Contributors

About

Close the deal - Ensure successful and profitable life sciences mergers and acquisitions

In the past year, the life sciences industry has seen a marked increase in M&A activity. Life sciences companies have already spent billions of dollars on these deals. Due to the increased price and complexity of collaborations, many life sciences companies are now turning to M&As as either an exit strategy or a way to grow their business.

American Conference Institute's Riding the New Wave of Life Sciences Mergers and Acquisitions will keep you well prepared by bringing you thoughtful, targeted and in-depth analysis. You also will benefit from the detailed written materials prepared specifically for this event. Take this opportunity to get the most updated and comprehensive information and advice you need regarding life sciences mergers and acquisitions.

Negotiating M&As in the life sciences arena is significantly different from deals in other industries. For life sciences companies, you need to know how to handle the unique challenges in valuing and conducting an accurate due diligence on a pipeline. In addition, there are specific regulatory and antitrust concerns that arise in life sciences companies that must be considered with an M&A, as well as distinctive representations and warranties in your deal.

Understand the nuts and bolts of M&A deals

For any M&A deal, there are a number of factors that need to be addressed. Before beginning any M&A, the company needs to consider the business reasons for entering into the transaction as well as the best structure for the deal. Ensuring a workable post integration process is also essential to a successful deal.

Contents & Contributors


RIDING THE NEW WAVE OF LIFE SCIENCES MERGERS & ACQUISITIONS
Larry Miller, Pfizer Inc. (New York, NY)
Usha Pillai, Ph.D., Pfizer Inc. (Groton, CT)
Barbara A. Kosacz, Cooley Godward Kronish LLP (Palo Alto, CA)

ADDRESSING THE ESSENTIAL COMPONENTS OF LIFE SCIENCES M&A DUE DILIGENCE
Catherine J. Dargan, Covington & Burling LLP (Washington, DC)
ADDRESSING THE ESSENTIAL COMPONENTS OF LIFE SCIENCES M&A DUE DILIGENCE
Larry Miller, Pfizer Inc. (New York, NY)

ADDRESSING THE ESSENTIAL COMPONENTS OF LIFE SCIENCES M&A DUE DILIGENCE
Jeffrey L. Wade, Lexicon Genetics Inc. (The Woodlands, TX)
DUE DILIGENCE IN LIFE SCIENCES MERGERS & ACQUISITIONS
R. King Milling Jr., Orrick, Herrington & Sutcliffe LLP (New York, NY)
M. Veronica Mullally, Orick, Herrington & Sutcliffe LLP (New York, NY)

VALUATION METHODOLOGIES
Matthew N. Murray, Ph.D., New York Private Equity (New York, NY)

VALUATION PHARMACEUTICAL COMPANY METHODOLOGIES AND PERSPECTIVE
Evan Lippman, AstraZeneca Pharmaceuticals LP (Wimington, DE)

VALUING LIFE SCIENCES COMPANIES AND ASSETS
Douglas H. Rogers, CBIZ Valuation Group (New York, NY)

OVERCOMING THE UNIQUE CHALLENGES IN PRIVATE V. PUBLIC M&A
Randall B. Sunberg, Partner, Morgan, Lewis & Bockius LLP (Princeton, NJ)

ASSESSING BUSINESS CONSIDERATIONS FOR M&A
Robert Ticktin, Amgen Inc. (Thousand Oaks, CA)
Paul Feuerman, Axonyx, Inc.; PharmAdvisors LLC (New York, NY)
Walter Lau, Onyx Pharmaceuticals (Emeryville, CA)
Keith A. Gregg, BioPharm Development Group, LLC (Brentwood, TN)

INTERPLAY OF M&A AND PARTNERING
Kenneth Clark, Wilson Sonsini Goodrich & Rosati (Palo Alto, CA)
GUARANTEEING A WINNING DEAL STRUCTURE THE COMPANY PERSPECTIVE
Tanya Dobash Berlage, Saul Ewing LLP (Baltimore, MD)

TRENDS IN LIFE SCIENCES M&A
Ivan G. Farman, Merrill Lynch & Co., Inc. (New York, NY)

UNDERSTANDING REPRESENTATIONS AND WARRANTIES IN M&A DEALS
Craig C. Bradley, Bell, Boyd & Lloyd LLC (Chicago, IL)

AVOIDING ANTITRUST DILEMMAS
Neal R. Stoll, Skadden, Arps, Slate, Meagher & Flom LLP & Affiliates (New York, NY)

MERGERS IN THE PHARMACEUTICAL AND MEDICAL DEVICE INDUSTRIES: HOW TO GET YOUR DEAL THROUGH THE ANTITRUST REVIEW PROCESS
Matthew J. Reilly, Federal Trade Commission (Washington, DC)

THE SIX REGULATORY ISSUES THAT MUST BE ADDRESSED IN A LIFE SCIENCES M&A
Stephen Paul Mahinka, Morgan, Lewis & Bockius LLP (Washington, DC)

GLOBAL ISSUES: LIFE SCIENCES M&A
James Farrington, Wiggin & Dana LLP (Stamford, CT)

STRUCTURING THE MILESTONE-BASED LIFE SCIENCES ACQUISITION: TAILS, TAXES, CONTROL
Jeffrey L. Quillen, Foley Hoag LLP (Boston, MA)

SUCCESSFUL POST-MERGER INTEGRATION PROCESSES
Usha Pillai, Ph.D., Pfizer Inc. (Groton, CT)

DEVELOPING A SYSTEMS APPROACH TO POST-CLOSING INTEGRATION
Andrew J. Sherman, Dickstein Shapiro LLP (Washington, DC)



DOCUMENT TYPES: PRESENTATIONS AVAILABLE: 0